MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574015 | Name: Melanotan II acetate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Melanotan II acetate is an agonist of melanocortin receptor 1 (MC1R), MC3R, MC4R, and MC5R. It has been shown to improve recovery of sciatic nerve function after mechanical injury and increase cisplatin-induced decreases in sensory nerve conduction velocity. Melanotan II acetate increases oxygen consumption and protein levels of uncoupling protein 1 (UCP1) in brown adipose tissue homogenates and decreases food intake, body weight, and serum levels of leptin, glucose, insulin, and cholesterol.

Chemical Structure

Melanotan II acetate
Melanotan II acetate
CAS#1036322-26-5 (acetate)

Theoretical Analysis

MedKoo Cat#: 574015

Name: Melanotan II acetate

CAS#: 1036322-26-5 (acetate)

Chemical Formula: C52H73N15O11

Exact Mass: 1083.5614

Molecular Weight: 1084.25

Elemental Analysis: C, 57.60; H, 6.79; N, 19.38; O, 16.23

Price and Availability

Size Price Availability Quantity
1mg USD 350.00 2 Weeks
5mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1036322-26-5 (acetate) 121062-08-6 (free base)
Synonym
Melanotan II acetate, MT II
IUPAC/Chemical Name
(3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide acetate
InChi Key
GTAMEWQATOUMGW-GBRHMYBBSA-N
InChi Code
InChI=1S/C50H69N15O9.C2H4O2/c1-3-4-16-36(59-29(2)66)44(69)65-41-25-42(67)55-20-11-10-18-35(43(51)68)60-47(72)39(23-31-26-57-34-17-9-8-15-33(31)34)63-45(70)37(19-12-21-56-50(52)53)61-46(71)38(22-30-13-6-5-7-14-30)62-48(73)40(64-49(41)74)24-32-27-54-28-58-32;1-2(3)4/h5-9,13-15,17,26-28,35-41,57H,3-4,10-12,16,18-25H2,1-2H3,(H2,51,68)(H,54,58)(H,55,67)(H,59,66)(H,60,72)(H,61,71)(H,62,73)(H,63,70)(H,64,74)(H,65,69)(H4,52,53,56);1H3,(H,3,4)/t35-,36-,37-,38+,39-,40-,41-;/m0./s1
SMILES Code
O=C(N[C@]([H])(C(N)=O)CCCCNC1=O)[C@H](CC2=CNC3=C2C=CC=C3)NC([C@H](CCCNC(N)=N)NC([C@](CC4=CC=CC=C4)([H])NC([C@H](CC5=CN=CN5)NC([C@@H](NC([C@@H](NC(C)=O)CCCC)=O)C1)=O)=O)=O)=O.CC(O)=O
Appearance
A crystalline solid
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Melanotan II acetate is an agonist of melanocortin receptor 1 (MC1R), MC3R, MC4R, and MC5R.
In vitro activity:
It was found that, despite a lack of influence on proliferation, MTII (melanotan II) potently inhibited the migration, invasion, and colony-forming capability of melanoma cells. By immunoblot and immunohistochemical analysis, it was found that MTII dose-dependently increased the phosphatase and tensin homolog (PTEN) protein level while reducing PTEN phosphorylation, which resulted in the inhibition of AKT/nuclear factor kappa B (NFκB) signaling. Consistently, MTII treatment inhibited cyclooxygenase II (COX-2) expression and prostaglandin E2 (PGE2) production in melanoma cells. Reference: Int J Mol Sci. 2020 Jan 20;21(2):681. https://pubmed.ncbi.nlm.nih.gov/31968661/
In vivo activity:
MT-II (melanotan II) injected into the rat nucleus accumbens significantly decreased consumption in both home cage and operant paradigms, and furthermore decreased appetitive responding to gain access to food. There was no development of conditioned taste avoidance or change in metabolic parameters following anorexic doses of MT-II. Reference: Neuropeptides. 2022 Dec;96:102289. https://pubmed.ncbi.nlm.nih.gov/36155088/

Preparing Stock Solutions

The following data is based on the product molecular weight 1,084.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wu JC, Tsai HE, Hsiao YH, Wu JS, Wu CS, Tai MH. Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. Int J Mol Sci. 2020 Jan 20;21(2):681. doi: 10.3390/ijms21020681. PMID: 31968661; PMCID: PMC7013727. 2. Chai B, Li JY, Zhang W, Wang H, Mulholland MW. Melanocortin-4 receptor activation inhibits c-Jun N-terminal kinase activity and promotes insulin signaling. Peptides. 2009 Jun;30(6):1098-104. doi: 10.1016/j.peptides.2009.03.006. Epub 2009 Mar 25. PMID: 19463742; PMCID: PMC2687409. 3. Eliason NL, Martin L, Low MJ, Sharpe AL. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022 Dec;96:102289. doi: 10.1016/j.npep.2022.102289. Epub 2022 Sep 16. PMID: 36155088. 4. Fortin SM, Chen J, Grill HJ, Hayes MR. The Mesencephalic Trigeminal Nucleus Controls Food Intake and Body Weight via Hindbrain POMC Projections. Nutrients. 2021 May 13;13(5):1642. doi: 10.3390/nu13051642. PMID: 34068091; PMCID: PMC8152732.
In vitro protocol:
1. Wu JC, Tsai HE, Hsiao YH, Wu JS, Wu CS, Tai MH. Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. Int J Mol Sci. 2020 Jan 20;21(2):681. doi: 10.3390/ijms21020681. PMID: 31968661; PMCID: PMC7013727. 2. Chai B, Li JY, Zhang W, Wang H, Mulholland MW. Melanocortin-4 receptor activation inhibits c-Jun N-terminal kinase activity and promotes insulin signaling. Peptides. 2009 Jun;30(6):1098-104. doi: 10.1016/j.peptides.2009.03.006. Epub 2009 Mar 25. PMID: 19463742; PMCID: PMC2687409.
In vivo protocol:
1. Eliason NL, Martin L, Low MJ, Sharpe AL. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022 Dec;96:102289. doi: 10.1016/j.npep.2022.102289. Epub 2022 Sep 16. PMID: 36155088. 2. Fortin SM, Chen J, Grill HJ, Hayes MR. The Mesencephalic Trigeminal Nucleus Controls Food Intake and Body Weight via Hindbrain POMC Projections. Nutrients. 2021 May 13;13(5):1642. doi: 10.3390/nu13051642. PMID: 34068091; PMCID: PMC8152732.
1. Schiöth, H.B., Müceniece, R., Mutulis, F., et al. Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides 18(7), 1009-1013 (1997). 2. Ter Laak, M.P., Brakkee, J.H., Adamn, R.A., et al. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur. J. Pharmacol. 462(1-3), 179-183 (2003). 3. Li, G., Zhang, Y., Wilsey, J.T., et al. Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression. J. Endocrinol. 182(1), 123-132 (2004).